Michael Seiberling

2.0k citations

45 papers · 1.6k indexed · h-index 21

Impact in

Hematology top 2%
- Chronic Myeloid Leukemia Treatments
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Transplantation 2
Hematology 6
- Chronic Myeloid Leukemia Treatments 5

Co-authors: Bin Peng (5 shared papers)Rolf Pokorny (6 shared papers)Renaud Capdeville (4 shared papers)Michael Hayes (3 shared papers)Catherine Dutreix (2 shared papers)Monique Ben‐Am (2 shared papers)Felix Waldmeier (2 shared papers)U Keller (2 shared papers)
Journals: The Journal of Clinical Pharmacology (5 papers)Antimicrobial Agents and Chemotherapy (4 papers)Vaccine (3 papers)Cancer Chemotherapy and Pharmacology (3 papers)Biopharmaceutics & Drug Disposition (2 papers)
Partner nations: Switzerland United States Germany

In The Last Decade

Michael Seiberling

43 papers receiving 1.5k citations

Peers

Countries citing papers authored by Michael Seiberling

Since Specialization

Citations

This map shows the geographic impact of Michael Seiberling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Seiberling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Seiberling more than expected).

Fields of papers citing papers by Michael Seiberling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Seiberling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Seiberling. The network helps show where Michael Seiberling may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Seiberling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Seiberling Line = papers co-authored together Michael Seiberling links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS Drug Metabolism and Disposition ·Hans-Peter Gschwind, Ulrike Pfaar, Felix Waldmeier, Markus Zollinger, Claudia Sayer, Peter Zbinden, Michael Hayes, Rolf Pokorny, Michael Seiberling, Monique Ben‐Am, Bin Peng, Gerhard Groß	2005	186
2	Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion The Journal of Clinical Pharmacology ·Bin Peng, Catherine Dutreix, Günther H. Mehring, Michael Hayes, Monique Ben‐Am, Michael Seiberling, Rolf Pokorny, Renaud Capdeville, Peter Lloyd	2004	131
3	Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects Cancer Chemotherapy and Pharmacology ·Ann E. Bolton, Bin Peng, Martine Hubert, Axel Krebs‐Brown, Renaud Capdeville, U Keller, Michael Seiberling	2004	126
4	Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects Cancer Chemotherapy and Pharmacology ·Catherine Dutreix, Bin Peng, Guenther H. Mehring, Michael Hayes, Renaud Capdeville, Rolf Pokorny, Michael Seiberling	2004	121
5	Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers Drug Metabolism and Disposition ·Felix Waldmeier, Ulrike Glaenzel, B. Wirz, Lukas Oberer, Dietmar G. Schmid, Michael Seiberling, Jessica Valencia, Gilles‐Jacques Rivière, Peter End, Sujata Vaidyanathan	2007	104
6	Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults Vaccine ·Isabel Leroux‐Roels, Eva Vets, Ralf Freese, Michael Seiberling, Françoise Weber, Camille Salamand, Geert Leroux‐Roels	2008	99
7	Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy Subjects Antimicrobial Agents and Chemotherapy ·Stephen Villano, Michael Seiberling, Walter A. Tatarowicz, Elizabeth Monnot-Chase, Dale N. Gerding	2012	82
8	Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers Biopharmaceutics & Drug Disposition ·Jamie J. Zhao, John Rogers, Sherry D. Holland, Patrick Larson, Raju D. Amin, Rita Haesen, Amanda Freeman, Michael Seiberling, Martin Merz, Haiyung Cheng	1997	76
9	Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans Xenobiotica ·Shirin Bruderer, Gérard Hopfgartner, Michael Seiberling, Janine Wank, Patricia N. Sidharta, Alexander Treiber, Jasper Dingemanse	2012	68
10	Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults Vaccine ·Michael Seiberling, Monica Bologa, Roger H. Brookes, Martina M. Ochs, Kerry W. Go, David Neveu, Thierry Kamtchoua, Peter Lashley, Tao Yuan, Sanjay Gurunathan	2012	58
11	Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers Clinical Therapeutics ·Gopal Krishna, Allen Moton, Lei Ma, Ishani Savant, Monika Martinho, Michael Seiberling, James F. McLeod	2009	49
12	62 Lack of systemic activity with intranasal mometasone furoate Journal of Allergy and Clinical Immunology ·Melvin D. Brannan, Michael Seiberling, David L. Cutler, Francis M. Cuss, Mel Affrime	1996	46
13	Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules Cancer Chemotherapy and Pharmacology ·Zariana Nikolova, Bin Peng, Martine Hubert, Michael Seiberling, U Keller, Yu-Yun Ho, Horst Schran, Renaud Capdeville	2004	45
14	Effects of oral posaconazole on the pharmacokinetics of sirolimus Current Medical Research and Opinion ·Allen Moton, Lei Ma, Gopal Krishna, Monika Martinho, Michael Seiberling, James F. McLeod	2009	44
15	Pharmacokinetics and Safety Profile of the Human Anti- Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers Antimicrobial Agents and Chemotherapy ·Hedvika Lazar, Michael P. Horn, Adrian W. Zuercher, Martin A. Imboden, Peter Durrer, Michael Seiberling, Rolf Pokorny, Christophe Hammer, Aloïs B. Lang	2009	43
16	Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteers Clinical Pharmacokinetics ·Ravi Anand, Michael Seiberling, Thierry Kamtchoua, Rolf Pokorny	2007	31
17	Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration Vaccine ·Valérie Künzi, J. Klap, Michael Seiberling, Christian Herzog, Katharina Hartmann, Oliver Kürsteiner, Ronald Kompier, Roberto Grimaldi, Jaap Goudsmit	2009	28
18	The effect of anastrozole on the single‐dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers British Journal of Clinical Pharmacology ·R. A. Yates, J. Wong, Michael Seiberling, Michael Merz, Winfried März, Michael A. Nauck	2001	23
19	Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers JAIDS Journal of Acquired Immune Deficiency Syndromes ·Gopal Krishna, Allen Moton, Lei Ma, M. Martinho, Michael Seiberling, James F. McLeod	2009	23
20	Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers Antimicrobial Agents and Chemotherapy ·Heena Patel, Arne F. Andresen, Andreas Vente, Hans‐Dietrich Heilmann, Will Stubbings, Michael Seiberling, Luis López Lázaro, Rolf Pokorny, Harald Labischinski	2011	23

About Michael Seiberling

Michael Seiberling is a scholar working on Transplantation, Hematology, Analytical Chemistry, Pharmacology and Sensory Systems, having authored 45 papers that have together received 1.6k indexed citations. Recurring topics across this work include Analytical Methods in Pharmaceuticals (5 papers), Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (3 papers), Immune Cell Function and Interaction (3 papers), Eosinophilic Disorders and Syndromes (3 papers), Antifungal resistance and susceptibility (3 papers), Immune Response and Inflammation (3 papers) and Pneumonia and Respiratory Infections (3 papers). The work is most often cited by research in Hematology (431 citations), Genetics (309 citations), Pharmacology (166 citations), Gastroenterology (101 citations) and Pharmaceutical Science (70 citations). Michael Seiberling has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Bin Peng, Rolf Pokorny, Renaud Capdeville, Michael Hayes, Catherine Dutreix, Monique Ben‐Am, Felix Waldmeier, U Keller, Martine Hubert and Allen Moton. Their work appears in journals such as The Journal of Clinical Pharmacology, Antimicrobial Agents and Chemotherapy, Vaccine, Cancer Chemotherapy and Pharmacology and Biopharmaceutics & Drug Disposition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact